Alto Neuroscience, Inc.
ANRO · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $11 | $13 | $10 | $11 |
| G&A Expenses | $0 | $6 | $6 | $0 |
| SG&A Expenses | $4 | $6 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $15 | $19 | $16 | $17 |
| Operating Income | -$15 | -$19 | -$16 | -$17 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $2 |
| Pre-Tax Income | -$14 | -$18 | -$15 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$18 | -$15 | -$15 |
| % Margin | – | – | – | – |
| EPS | -0.52 | -0.65 | -0.56 | -0.56 |
| % Growth | 20% | -16.1% | 0% | – |
| EPS Diluted | -0.52 | -0.65 | -0.56 | -0.56 |
| Weighted Avg Shares Out | 27 | 27 | 27 | 27 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$13 | -$17 | -$14 | -$15 |
| % Margin | – | – | – | – |